Quest Diagnostics Inc (NYSE:DGX) announced results from its 2026 Annual Meeting of Stockholders. Based on an SEC filing, the $21.4 billion healthcare diagnostics company maintains a "GOOD" financial health score.
Shareholders elected all nominated directors for terms through 2027. Elected directors include Robert B. Carter (93,821,069 votes for), James E. Davis (88,799,800), Luis A. Diaz, Jr., M.D. (93,909,369), Tracey C. Doi (93,649,938), Vicky B. Gregg (83,814,387), Wright L. Lassiter, III (93,802,306), Timothy L. Main (88,302,767), Denise M. Morrison (89,808,461), Gary M. Pfeiffer (86,302,153), Timothy M. Ring (81,917,543), and Timothy C. Wentworth (93,427,490).
Executive compensation was approved on an advisory basis: 86,869,738 for, 7,152,448 against. PricewaterhouseCoopers LLP was ratified as auditor: 97,340,034 for, 5,809,995 against.
A proposal for an independent board chairman failed: 23,999,636 for, 69,792,819 against.
Bond.az reports based solely on the company’s official press release and SEC filing.
